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Abstract
Background: Gene targeting in nonhuman primates has the potential to produce critical animal
models for translational studies related to human diseases. Successful gene targeting in fibroblasts
followed by somatic cell nuclear transfer (SCNT) has been achieved in several species of large
mammals but not yet in primates. Our goal was to establish the protocols necessary to achieve
gene targeting in primary culture of adult rhesus macaque fibroblasts as a first step in creating
nonhuman primate models of genetic disease using nuclear transfer technology.
Results: A primary culture of adult male fibroblasts was transfected with hTERT to overcome
senescence and allow long term in vitro manipulations. Successful gene targeting of the HPRT locus
in rhesus macaques was achieved by electroporating S-phase synchronized cells with a construct
containing a SV40 enhancer.
Conclusion: The cell lines reported here could be used for the production of null mutant rhesus
macaque models of human genetic disease using SCNT technology. In addition, given the close
evolutionary relationship and biological similarity between rhesus macaques and humans, the
protocols described here may prove useful in the genetic engineering of human somatic cells.
Background
Rhesus macaque models of human genetic disease would
be very useful for translational research. Although mouse
"knockouts" have provided much basic information
regarding the effects of gene disruption, for some genes,
null mutations in the mouse ortholog of a human disease
gene does not result in a phenotype that completely
matches the human disease. Thus, there are either no or
limited animal models for many human genetic diseases
[1]. Furthermore, non-human primates are often pre-
ferred for translational research due to close similarities to
humans in behavior, anatomy, physiology, and genetics
[2-6].
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Currently, the vast majority of genetic models of human
disease in mammals have utilized the mouse as an exper-
imental animal [7]. This is due to the relative ease with
which genetically modified animals, including loss-of-
function and knock-in mutations, can be produced by
transfecting ES cells and creating chimeric animals with
germline changes [7]. Unfortunately, although ES cells
have been derived from primates including rhesus
macaques, they have not been shown to contribute to chi-
meras.
Null mutant sheep, goats, pigs and cattle have been pro-
duced using an alternative approach: gene targeting in
somatic cells followed by nuclear transfer to enucleated
oocytes (SCNT; reproductive cloning) [8-18]. Gene target-
ing in human fibroblasts has also been achieved [19-25].
Because many different experimental protocols have been
applied to achieve gene targeting in mammalian fibrob-
lasts, we wished to determine which protocols would sup-
port efficient gene targeting in rhesus macaque fibroblasts
as a first step in creating null mutant rhesus macaques
using SCNT.
The HPRT gene was the first gene disrupted in the mouse
[26]. There were several reasons for this, including the fact
that mutations in the human ortholog results in a severe
neurodevelopmental disorder known as Lesch-Nyhans
disease, and the fact that mouse HPRT null ES cells could
be selected for by adding compounds that would kill any
cells expressing the HPRT protein [27-29]. Moreover,
HPRT is located on the X chromosome; therefore disrup-
tion of only one copy of the gene in male XY cells is suffi-
cient to generate a phenotype. Unfortunately, although
mice with HPRT null mutations did exhibit a 50% loss of
dopamine in the striatum [30], they did not exhibit the
same spontaneous behavioral abnormalities seen in
humans with Lesch-Nyhans disease [31]. We chose to tar-
get the HPRT gene in male rhesus macaque cells for three
reasons: we could select for null mutant cells in culture; it
would only be necessary to disrupt one allele to observe a
phenotype; and because an animal model with the same
behavioral deficits seen in Lesch-Nyhan's disease does not
currently exist.
Several different techniques, and combinations of tech-
niques, were evaluated before we determined a set of pro-
tocols that resulted in efficient production of gene
targeted fibroblasts in rhesus macaques. In this report, we
describe what did and did not work for us. One of the
important keys to our success was the use of cell cycle syn-
chronization prior to transfection and the inclusion of a
SV40 enhancer in the targeting construct [32].
Results
hTERT transfection of fibroblasts
In preliminary studies with rhesus fibroblasts, we had dif-
ficulty maintaining these cells in culture long enough to
support gene targeting procedures due to senescence.
hTERT transfection has been shown to prevent senescence
in rhesus fibroblasts [33,34]. To extend the time that
fibroblasts could be cultured, we electroporated adult
male rhesus macaque fibroblasts with a construct contain-
ing a human telomerase reverse transcriptase (hTERT)
expression cassette (pCI-neo-hTERT, courtesy of Dr. Rob-
ert Weinberg). After G418 selection, cells were passaged
continuously until after the empty vector control fibrob-
lasts reached senescence. Control fibroblasts entered
senescence after 46 population doublings (Figure 1)
whereas the hTERT-transfected cells showed no change in
growth rate, no evidence of senescence, and were still
dividing after more than 24 weeks (Figure 1).
To verify that the hTERT-transfected fibroblasts carried
integrated copies of the transfected hTERT gene, genomic
DNA was extracted and PCR analysis was performed to
screen for the presence of the construct (Figure 2A). The
PCR assay demonstrated that hTERT was likely stably inte-
grated in the rhesus fibroblast genomic DNA (Figure 2B).
To determine if hTERT was expressed in the rhesus fibrob-
lasts, RNA was extracted from NEOr cells and reverse tran-
scribed to cDNA. Two sets of primers were used. One set
Extension of lifespan by exogenous telomeraseFigure 1
Extension of lifespan by exogenous telomerase. Early 
passage rhesus macaque fibroblasts were transfected with 
vector pCi-neo carrying no insert (Vector) or the hTERT 
cDNA (hTERT). Transfected cells were maintained in log 
phase growth and counted at the time points shown, with 
the age of each culture expressed in population doublings.
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of primers amplified a 145 bp fragment from the coding
region. The other set of primers amplified a 636 bp frag-
ment which included a portion of the TERT 3' UTR not
included in the construct. This made it possible to use a
reverse primer that would anneal to wild type TERT tran-
script but not transcript from the construct (Figure 3).
We were able to further test whether the TERT expressed in
the transfected rhesus macaque fibroblasts originated
from the introduced construct or the endogenous gene by
sequencing the RT-PCR product. This was possible
because pCI-neo-hTERT contains the human TERT cds,
which differs from rhesus macaque TERT in 3 positions of
the 145 bp coding amplicon described above. Sequencing
of this amplicon indicated that the TERT expressed in the
transfected rhesus macaque fibroblasts was derived from
pCI-neo-hTERT, not the endogenous TERT gene.
A second population of hTERT-transfected fibroblasts was
also made, which we maintained under selection for 20
weeks. In the 8 gene targeting experiments represented in
Table 1, either the first (Exps. 1–7) or the second (Exp. 8)
population of hTERT-transfected fibroblasts were used. In
general, pCI-neo-hTERT transfected fibroblasts generated
a greater average number of PUROr colonies than wild
type fibroblasts after being electroporated with the target-
ing construct (84 colonies with wild type cells vs. a mean
of 146 colonies with TERT-transfected cells {experiments
2–5}). After S-phase synchronization/electroporation
(see below), pCI-neo-hTERT transfected fibroblasts
returned to a proliferative state sooner than wild type
fibroblasts. A total of 8 targeting experiments were per-
formed with the hTERT-transfected fibroblasts, which
yielded 21 colonies displaying the HPRT null phenotype
(Table 1). An attempt to target wild type fibroblasts was
unsuccessful (data not shown).
Transfection strategies
To compare transfection methods, rhesus macaque fetal
fibroblast cells were transfected with linearized pCMV-
Sport-E-gal (Gibco Life Technologies, Grand Island, NY)
using three commercially available cationic lipids: Lipo-
fectamine (Life Technologies, Inc., Gaithersburg, MD);
SuperFect (Qiagen, Hilden, Germany); and FuGENE6
(Roche Diagnostics Corporation, Indianapolis, IN). The
RT-PCR for TERT expression in rhesus fibroblast cellsFigure 3
RT-PCR for TERT expression in rhesus fibroblast 
cells. a) CDS = coding region, T2A = hTERT-T2A, T2B = 
hTERT-T2B, ENF3 = MK TERT ENF3, ENR3 = MK TERT 
ENR3, blue line = portions of TERT included in pCI-neo-
hTERT construct. b) M = 100 bp marker; WT = wild type 
rhesus fibroblasts; ES = rhesus embryonic stem cells; TTF = 
TERT transfected fibroblasts (experiment #8, HPRT null 
clone) T3' = Amplicons of 3' UTR TERT found in endog-
enous TERT mRNA but not present in construct hTERT 
mRNA; TC = Amplicons of coding TERT found in both 
endogenous and construct hTERT mRNA.
hTERT genomic PCR assayFigure 2
hTERT genomic PCR assay. a) pCI-neo-hTERT con-
struct. Primers (arrows) amplify a 2960 bp product that 
includes the 3' end of the hTERT cassette and the 5' end of 
the NEOr cassette. b) M = 1 kb Marker, WT = wild type rhe-
sus fibroblasts, HTF = TERT transfected fibroblasts (Experi-
ment #8, HPRT null clone).
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results of these chemotransfection methods were com-
pared with electroporation. With Lipofectamine, only one
E-Gal positive cell out of 300,000 was seen 7 days after
transfection. With SuperFect, no E-Gal expressing cells
were observed 7 days after transfection. FuGENE6 trans-
fection resulted in .02% E-Gal positive cells 7 days after
transfection. FuGENE6 was also less toxic to cells. In con-
trast, electroporation resulted in 1 – 5% of the transfected
cells expressing E-gal after 7 days. These results, and a
report by Zwaka and Thomson [35] indicating that the
chemical methods of transfection were not effective for
gene targeting in human ES cells, prompted us to focus on
electroporation for our gene targeting experiments.
To achieve gene targeting in adult rhesus macaque fibrob-
lasts, several different strategies for construct design were
implemented. Two promoterless constructs were engi-
neered, one with a neomycin resistance (NEOr) selection
cassette and the other with a puromycin resistance
(PUROr) selection cassette. Both contained an internal
ribosomal entry site (IRES). In targeting experiments uti-
lizing these constructs, no apparent NEOr or PUROr colo-
nies were observed (Table 2). Electroporation of
fibroblasts with a targeting construct containing a phos-
phoglycerate kinase (PGK) promoter and the neomycin
cassette resulted in numerous G418 colonies. However,
none were resistant to 6TG, indicating that the HPRT gene
had not been targeted (Table 2).
Our failure to achieve gene targeting in rhesus macaque
fibroblasts using conventional approaches prompted us
to consider alternative methods. Mir and Piedrahita [32]
discussed the difficulties in obtaining gene targeting in
somatic cells and reported that two techniques, thymidine
block of cell cycling and the inclusion of a SV40 enhancer
sequence in a vector, dramatically improved gene target-
ing in somatic cells. This motivated us to test these tech-
niques with our pCI-neo-hTERT transfected rhesus
fibroblasts.
S-phase Synchronization
We performed a cell cycle analysis of adult rhesus
macaque fibroblasts. Cells were treated with thymidine
for 12, 18, 24, 30 and 36 hours and harvested for cell cycle
analysis. Thymidine treatment for 24 hours resulted in the
highest number of cells in S-phase (80%) (Table 3; Figure
4).
To test the hypothesis that S-phase arrested rhesus
macaque fibroblasts would reduce random integration of
the targeting construct, we synchronized cells with thymi-
dine treatment and then transfected them with a targeting
construct containing the neomycin resistance gene driven
by the PGK promoter. This hypothesis was confirmed as
we observed a 28 fold reduction in the rate of random
integration of the targeting construct after S-phase syn-
chronization as compared to non-synchronized cells.
However, no targeted events occurred in either experi-
ment (Table 4).
Targeting construct with SV 40 enhancer element
An HPRT targeting construct with an SV40 nuclear localiz-
ing DNA was created (Figure 5A). The inclusion of the
SV40 nuclear localizing DNA was previously reported to
increase gene targeting in bovine fibroblasts, especially
when used in conjunction with S-phase synchronization
[32]. This construct contained a total of 10.3 Kb of homol-
ogy to the HPRT locus, 3.9 Kb at the short arm and 6.4 Kb
at the long arm. The HPRT sequence was isogenic with the
fibroblasts used for targeting. The selection cassette
included the puromycin resistance gene driven by the
PGK promoter.
Transfection and selection
We utilized the Mir and Piedrahita [32] recommendation
of 4 pulses of electroporation at 450 V, which represented
a significant change from our normal electroporation
parameters. After electroporation, cells that were thymi-
dine blocked did not divide for four days; therefore, puro-
mycin selection was not initiated until 4 days after
electroporation. The specific sequence and timing of selec-
Table 1: Results of targeting experiments with the pHPRT PURO SV40 vector in S-phase cell synchronized hTERT transfected 
fibroblasts.
Exp # of cells PUROr+ 8AGr+ 6TGr+ PCR + Karyotype
1 107 cells NC* 1 1 1 Abnormal
2 107 cells 160 2 2 2 ND**
3 107 cells 170 7 7 6 ND**
4 107 cells 132 6 6 6 ND**
5 107 cells 122 3 3 2 ND**
6 107 cells 221 1 1 1 Normal
7 107 cells 152 0 0 0 ND**
8 107 cells 410 1 1 1 Normal
*NC = not counted, **ND = not done
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tion was crucial in identifying HPRT-null (targeted)
fibroblasts. Critical parameters that were identified by Dr.
Piedrahita (personal communication) included selection
on 96 well plates at 5,000 cells per well (low cell density)
and the use of puromycin selection. Selection for HPRT
null mutant cells was more effective when 8AG selection
preceded 6TG selection.
Generation of HPRT null mutant rhesus macaque 
fibroblasts
The combination of cell synchronization and the electro-
poration of pCI-neo-hTERT transfected fibroblasts with a
targeting construct containing the SV40 enhancer resulted
in targeting of the HPRT locus in rhesus macaque fibrob-
lasts (Table 1). A total of 8 targeting experiments were per-
formed; 21 colonies had the HPRT null phenotype.
In order to screen for targeted clones, primers were
designed that produced an amplicon if the gene was not
targeted and did not produce an amplicon if the gene was
targeted (Figure 5). Nineteen of these colonies were veri-
fied by PCR to be targeted (Table 1). Of the remaining 2
colonies, one was further analyzed and found to contain
an insertion of exons 7 and 8 from the targeting construct
into the HPRT locus, without replacement, causing a
frameshift that resulted in a stop codon at exon 7.
PCR analysis of genomic DNA demonstrated the persist-
ence of the pCI-neo-hTERT in HPRT targeted clones gen-
erated in experiments 1 and 8 (Table 1). RT-PCR
demonstrated TERT expression in the HPRT null clones
from experiments 1 and 8 (Figure 3B), but not experiment
6.
Cytogenetic analysis indicated that the HPRT null clone
from experiment 1 had an abnormal karyotype involving
a balanced translocation of chromosome 19 (data not
shown). However, targeted clones from experiments 6
and 8 (Figure 6) were karyotypically normal.
An attempt to target wild type fibroblasts was unsuccess-
ful.
Discussion
When deciding how to disrupt a gene in a mammalian
somatic cell, there are a number of choices the investigator
must make. Which method of transfection should be
used? Which type of vector design and culture conditions
should be chosen to enrich for targeted cells? An addi-
tional issue which must be addressed for rhesus macaques
is: how to obtain a sufficient supply of fibroblasts to suc-
cessfully target a gene given that many of the transfected
cells will become senescent prior to completion of selec-
tion procedures. We found that identifying the right com-
bination of approaches to successfully disrupt the HPRT
gene in fibroblasts in rhesus macaques to be quite chal-
lenging.
There are three main approaches to transfecting cells for
gene targeting: chemical, electroporation and viral. The
Cell cycle analysisFigure 4
Cell cycle analysis. DNA histogram of rhesus fibroblasts 
stained with Vindelov's reagent after 24 hour treatment with 
thymdine (Cell Analysis Facility, UNMC). The percentage of 
cells in S phase as obtained by the computer fit model of 
Modfit LT. G0/G1: 19.56%, G2/M: 0%; S: 80.44%
Table 2: Results of conventional HPRT targeting strategies in hTERT transfected fibroblasts
Vector Promoter IRES Antibiotic Coloniesr/5 × 106 cells Targeting events
pMK HPRT INEO None Yes NEO 0 0
pMK HPRT IPURO None Yes PURO 0 0
pHPRT+/- PGK No NEO 282 0
Table 3: Percentage of fibroblasts in the S-Phase of the cell cycle 
by a 2 mM thymidine treatment for times ranging from 12 to 36 
hours.
Hours 12 18 24 30 36
% Cells S-Phase 21% 27% 80% 45% 14%
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success rate of these different approaches has varied
greatly depending on the technique and in which lab the
targeting occurred. For example, efficient gene targeting
has been reported with chemical transfection methods in
fibroblasts from sheep [14] and pigs [36,37]. Electropora-
tion has been used to introduce targeting constructs into
fibroblasts from humans [20], sheep [11], pigs
[9,10,38,39] and cows [17,32]. Adeno-associated vectors
have been used for gene targeting in human [21] and cow
[40] somatic cells.
Although we have not systematically tested all possible
methods of gene targeting in rhesus macaques, we did
examine a number of different methods. We initially
attempted gene targeting in rhesus macaque fibroblasts
using chemical methods. These attempts were unsuccess-
ful. Others have also reported difficulties with this
approach for gene targeting [35]. We were able to achieve
successful gene targeting with electroporation, but only
after utilizing a SV40 enhancer in the targeting construct
and synchronizing the cell cycle of the fibroblasts.
It is difficult to explain why gene targeting approaches that
are reported to be very efficient in one lab are not success-
ful in another. When we applied different methods of
gene targeting to rhesus fibroblasts, we followed the rec-
ommended protocols for other species. In our hands, only
one approach was successful for rhesus macaque fibrob-
lasts [32]. It is possible that modifications of the other
protocols would have resulted in success in rhesus
macaques. Although we did not attempt the use of viral
vectors for gene targeting in rhesus macaque fibroblasts,
their successful use in human and cow somatic cells sug-
gests that this would be a possible method for performing
gene targeting in rhesus macaque fibroblasts [21,40].
Fetal fibroblasts are used for gene-targeting in studies for
most mammals. For rhesus macaques, obtaining a suffi-
cient supply of such cells for experimentation is difficult.
Further, in our preliminary experiments with fetal fibrob-
lasts, we found that many of these cells were becoming
senescent towards the end of the selection procedures.
Extending the lifespan of adult fibroblasts by transfecting
them with TERT, allowed us to obtain a sufficient supply
of cells to test various gene targeting methods and avoid
senescence. It should be noted that in one of our targeted
clones (experiment 6, Table 1), hTERT was no longer
expressed. It is possible that the construct was never inte-
grated in this clone or that it was silenced at some point
during gene targeting selection.
Long term culture of somatic cells necessary for gene tar-
geting can result in chromosomal abnormalities. In our
study, a chromosomal translocation was observed in one
of the targeted clones (data not shown). However, we
were able to produce targeted clones that did not exhibit
any detectable karyotypic abnormalities (Figure 6). It is
possible that the expression of hTERT in the pCI-neo-
hTERT transfected fibroblasts protected them from under-
going crisis and transformation.
PCR screening strategyFigure 5
PCR screening strategy. a) A 3.9 kb PCR band occurs in 
the non-targeted wild type rhesus macaque fibroblast DNA. 
The reverse screening primer anneals to the deleted part of 
exon 6. If a targeting event has occurred, there will be no 3.9 
kb PCR band since that part if exon 6 has been deleted. b) M 
= 1 kb Marker, HTF = HPRT targeted fibroblasts, WT = wild 
type rhesus fibroblasts, ATM = ataxia telangiectasia mutated 
(positive control).
Table 4: Reduction of random integration by S-phase synchronization
Targeting Vector S-phase synchronization # of cells G418rcolonies
pHPRT+/- No 107 cells 564
pHPRT+/- Yes 107 cells 20
The targeting vector used in this experiment did not contain the SV40 enhancer.
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The current studies provide a workable protocol for pro-
ducing genetically modified non human primate (NHP)
fibroblasts. However, before these cells can be used for
SCNT it will be necessary to remove the hTERT construct.
hTERT expressing sheep fibroblasts have been shown to
result in blastocysts at normal rates after SCNT, but fetuses
did not survive past 40 days of development suggesting
that the hTERT may have negatively impacted develop-
ment at this stage [41]. In addition, constitutive expres-
sion of hTERT might complicate phenotype analysis.
Dysregulation of TERT is thought to be a contributing fac-
tor in cancer development [42]. Thus, one approach to
creating gene targeted NHPs will be to introduce TERT
into fibroblasts, perform gene targeting, remove the TERT
vector, confirm euploidy and then perform SCNT.
Conclusion
Although many protocols have been published for gene
targeting in mammalian somatic cells, most were ineffec-
tive in our hands when we attempted to disrupt the HPRT
gene in rhesus macaque fibroblasts. The critical parame-
ters for successful gene targeting in primary culture of rhe-
sus macaque fibroblasts included hTERT transfection, cell
synchronization in S-phase and inclusion of a SV40
enhancer in the targeting construct. The cell lines reported
here, with the removal of the TERT vector, could be used
for the production of null mutant rhesus macaque models
of human genetic disease using SCNT technology. In addi-
tion, given the close evolutionary relationship and biolog-
ical similarity between rhesus macaques and humans, the
protocols described here may prove useful in the genetic
engineering of human somatic cells.
Karyotype analysis of HPRT targeted cellsFigure 6
Karyotype analysis of HPRT targeted cells. G-banded karyotype from the HPRT null clone (from experiment 8) showing 
a normal male rhesus macaque chromosome complement.
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Methods
Generation of hTERT transfected fibroblasts
Early passage of primary culture fibroblasts derived from
an ear biopsy of a 16 year old male rhesus macaque (ani-
mal #20109, Oregon National Primate Research Center)
were grown to confluency on a 10 cm tissue culture dish
(Becton Dickenson, Franklin Lakes, NJ). Cells were
trypsinized and electroporated at 0.260 kV, 1 × 103 PF in
500 Pl of basal DMEM (Gibco, Carlsbad, CA) at 4°C with
10 Pg of linearized pCI-neo-hTERT (courtesy of Dr. Robert
Weinberg). Transfected cultures were selected with 400
Pg/ml Geneticin (G418 – Gibco, Carlsbad, CA) and sub-
sequently passed at confluency over the course of 24
weeks. Low passage NEOr cells were frozen for future use.
Clonal hTERT expressing cell lines were generated by elec-
troporating wild type fibroblasts with four pulses of 0.450
volts, 50 PF and then plating at 5,000 cells/well on 96-
well plates with Geneticin containing media.
PCR screening of rhesus fibroblasts for presence of the 
hTERT construct
Genomic DNA was extracted from pCI-neo-hTERT trans-
fected fibroblasts that had been passaged 13 times. PCR
was performed with 200 ng of genomic DNA (purified
with the PureGene Genomic Purification Kit, Gentra Sys-
tems, Minneapolis, MN according to manufacturer's
instructions) and primers TERT/NEO F1(5'-AACGTTC-
CGCAGAGAAAAGA-3') and TERT/NEO R1(5'-TGTCT-
GTTGTGCCCAGTCAT-3'). PCR conditions were as
follows: Initial denaturing step, 95°C for 2 minutes; 34
cycles of 95°C for 30 seconds, 56°C for 30 seconds and
72° for 3 minutes; 72°C for 7 minutes. The expected size
of the PCR product was 2.9 kb.
RT-PCR analysis of expressed TERT
Analysis of TERT expression was performed with 2 Pg of
rhesus RNA isolated from embryonic stem cells (ORMES-
6, Oregon National Primate Research Center), wild type
fibroblasts, and pCI-neo-hTERT transfected fibroblasts.
RNA was extracted using Trizol (invitrogen, Carlsbad, CA)
as recommended by the manufacturer. DNase1 (Invitro-
gen, Carlsbad, CA) was used to remove any contaminat-
ing DNA. RNA was then reverse transcribed according to
the manufacturer's protocol with Superscript III (Invitro-
gen, Carlsbad, CA). PCR was performed on the cDNA
using FastStart High Fidelity Polymerase (Roche Applied
Science, Indianapolis, IN). Primers MK TERT ENF3 (5'-
TCCTGCTCAAGCTGACTCAA-3') and MK TERT ENR3 (5'-
AAGGTCAGGGTGATGAGTGG-3') amplified a 636 bp
fragment expressed by the endogenous TERT gene but not
pCI-neo-hTERT. Primers hTERT-T2A (5'CGGAAGAGT-
GTCTGGAGCAA-3') and hTERT-T2B (5'-GGATGAAGCG-
GAGTCTGGA-3') amplified a 145 bp TERT coding
sequence fragment expected to be expressed by both the
endogenous TERT gene and pCI-neo-hTERT. PCR condi-
tions were as follows: Initial denaturing step, 95°C, 2
minutes; 34 cycles of 95°C for 30 seconds, 53°C for 30
seconds and 72°C, 1 minute; 72°C for 7 minutes.
Construction of a rhesus macaque HPRT targeting vector
The targeting vector was designed to delete 32 base pairs
of the rhesus HPRT exon 6 and replace it with a puromy-
cin resistance (PUROr) gene driven by the phosphoglycer-
ate kinase (PGK) promoter. This selection cassette was
PCR amplified from pKO Select PURO (Stratagene,
LaJolla, CA). Both the 5' (short arm) and the 3' (long arm)
of the homologous regions of the construct were PCR
amplified from genomic DNA obtained from an adult
male rhesus macaque (animal # 20109, Oregon National
Primate Research Center). Total length of homology was
10.3 Kb. An SV40 sequence was inserted 3' to the 3' arm
to increase nuclear import of the construct. pKO Scram-
bler V916 (Stratagene, La Jolla, Ca) was used as the back-
bone for the targeting construct.
The 5' end of the construct, containing a 3.9 Kb fragment
that spanned the 3' end of intron 5 to the 5' end of exon
6, was amplified with the primer pair HPRT ShortArm,
forward 5'-GGAAGATCTTAATGGTGGACTTGTGTTCTAA-
3' and HPRT ShortArm, reverse 5'-GGAAGATCTCCTGAC-
CAAGGAAAGCAAAG-3'. Due to a high GC content in the
amplified region, the Advantage GC Genomic Polymerase
Mix (BD Biosciences Clontech, Mountain View, CA) was
used for this PCR. PCR conditions were as follows: Initial
denaturing step, 94°C for 1 minute; 2 cycles of 94°C for
10 seconds and 60°C for 9 minutes; 27 cycles of 94°C for
10 seconds and 62°C for 9 minutes; 62°C for 10 minutes.
The 3' end of the construct, containing a 6.4 Kb fragment
that spanned the 3' end of intron 6 to the 5' end of exon
9, was amplified with primer pair HPRT LongArm, for-
ward 5'-CTAGCTAGCGGATTTTGAGCCCCCTTACA-3'
and HPRT LongArm, reverse 5'-CTAGCTAGCT-
GGCCACAGAACTAGAACATTGA-3'. PFU Ultra Polymer-
ase (Stratagene, LaJolla, CA) was used for this PCR. PCR
conditions were as follows: Initial denaturing step, 95°C
for 2 minutes; 29 cycles of 95°C for 30 seconds, 60°C for
30 seconds and 72°C for 14 minutes; 72°C for 10 min-
utes.
A SV40 nuclear localizing DNA sequence was PCR ampli-
fied from pIRES2-EGFP (BD Biosciences Clontech, Moun-
tain View, CA) with primers SV40, forward
5'GTCGACCCAGCTGTGGAATGTGTGTC-3' and SV40,
reverse 5'-GTCGACAACTGGGCGGAGTTAGGG-3' and
PFU Ultra Polymerase (Stratagene, LaJolla, CA). The SV40
fragment was subcloned into pPCR-Script AMP SK(+)
cloning vector (Stratagene, LaJolla, CA). The pPCR-Script
vector containing the SV40 fragment was digested with Sal
1 and the SV40 fragment was gel isolated and cloned into
the SAL 1 site of the targeting vector as described above.
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The targeting vector was linearized with Not1 enzyme
overnight, heat inactivated at 65° for 20 minutes, isopro-
panol precipitated, washed in 70% ethanol, dried at room
temperature for 5 minutes and resuspended in water at a
concentration of 1–2 Pg/ul.
Previous Targeting Vectors
All previous targeting vectors, ie, the ones that failed, had
the same regions of homology with the exception that
pHPRT PURO SV40 had a larger deletion in exon 6.
pHPRT +/- used PGK NEO as a selection cassette instead
of PGK PURO.
E-gal Transfection Methods
Lipofectamine (invitrogen, Carlsbad, CA), SuperFect
(Qiagen, Hilden, Germany) and FuGENE 6 (Roche, Basel,
Switzerland) were all tested for their ability to transfect
rhesus fetal fibroblasts with the vector pCMV-sport-E-gal
according to the manufacturers' instructions. One group
of cells were electroporated at .260 kV, 1 × 103 PF in 500
PL of basal DMEM with 20 Pg of linearized pCMV-sport-
B-gal at 4 °C.
After transfection, cells were incubated at 37°C for 7 days
and then stained with X-gal. The percent of cells trans-
fected was calculated by comparing the number of blue
cells to the number of cells plated.
Cell Cycle Analysis
hTERT transfected fibroblasts were grown to 70% conflu-
ency on 10 cm tissue culture dishes. Five tissue culture
dishes containing hTERT transfected fibroblasts received
thymidine (Sigma, St. Louis, Mo.), added to a concentra-
tion of 2 mM, in the growth media. Another 5 tissue cul-
ture dishes received growth media without thymidine.
At time intervals of 12, 18, 24, 30 and 36 hours after treat-
ment, one thymidine-treated dish and one control dish
were trypsinized and the cells counted. Pelleted cells were
resuspended at one million per ml in Vindelov's Reagent
and incubated one hour prior to DNA cell cycle analysis.
Targeting of HPRT in fibroblasts using electroporation
hTERT transfected and wild type rhesus macaque fibrob-
lasts were grown in Dulbecco's Modified Eagle Media (D-
MEM) media (Gibco, Carlsbad, CA) containing 12% fetal
bovine serum (FBS) at 37°C, 5% CO2. When cells reached
80% confluency on a 300 cm2 flask (Becton Dickinson,
Franklin Lakes, NJ), growth media containing 2 mM thy-
midine (Sigma, St. Louis, MO) was placed on the cells for
24 hours. Cells were then trypsinized and 10 million cells
electroporated (Gene Pulser II – Bio-Rad, Philadelphia,
PA) with a 20 Pg Not1 linearized pHPRT PURO SV40 con-
struct at 4°C (in 800 Pl basal D-MEM) in a 4 mm gap
cuvette (Bio-Rad, Philadelphia, PA). Cells were pulsed
four times at 0.450 kV, 50 PF. Growth media was added
and cells plated onto 96 well plates (Becton Dickinson,
Franklin Lakes, NJ) at 5000 cells/well.
Selection Procedures
Four days after electroporation, cells were incubated in
selection media containing 7.5 Pg/ml puromycin (Sigma,
St. Louis, MO). Four days after this, puromycin-resistant
(Puror) colonies were counted. These colonies were then
placed under selection for HPRT by incubating them in
media containing 50 Pg/ml 8-Azaguanine (8AG, Sigma,
St. Louis, MO) for 6 days. 8AG resistant colonies were
passed onto 2 cm2 dishes (Nunc, Rochester, NY). HPRT
selection was continued by incubating the 8AG resistant
colonies with 80 PM 6-Thioguanine (6TG, Sigma, St.
Louis, MO) for 10–14 days.
PCR screening strategy for HPRT targeted clones
Genomic DNA from 6TG/8AG resistant clones was
extracted using the PureGene Genomic DNA Purification
Kit (Gentra Systems, Minneapolis, MN). PCR screening
was performed with the Advantage GC genomic polymer-
ase (Clontech, Mountain View, CA). The primer pair used
was MK HPRT INT5F (5'-TAATGGTGGACTTGTGTTCTAA-
3') and MK HPRT EX6R (5'-TTGCGACCTTGACCATCT-
3'). Because the reverse primer contained sequence that
was deleted from the targeting construct, an amplicon
would be expected to be present in wild type cells but not
in HPRT targeted cells. The expected size of the PCR prod-
uct was 3.9 Kb. Ataxia telangiectasia (ATM) primers,
AEX1b (5'-GTCAGTCGTGTGGCCGCTCTCTACTGTC-3')
AEX6 (5'-CTGCCTGGAGGCTTGTGTTGAGGCTGATAC-
3'), were used as positive controls. The ATM PCR product
expected size was 5 Kb. The PCR conditions were as fol-
lows: Initial denaturing step, 94°C, 1 minute; 2 cycles of
94°C for 10 seconds and 60° for 9 minutes; 27 cycles of
94°C for 10 seconds, 62°C for 9 minutes; 62°C for 10
minutes.
Cytogenetic analysis
Cytogenetic analysis was performed on the HPRT null
fibroblast clones following standard GTW-banding proce-
dures. Specifically, 30 minutes prior to harvest, cells were
exposed to Colcemid (0.1 Pg/mL). Following hypotonic
treatment (0.7% Na citrate for 25 minutes), the prepara-
tions were fixed 3 times with methanol:glacial acetic acid
(3:1). Metaphase cells were banded with Wright stain and
20 metaphase cells were analyzed. Images were acquired
using the Cytovision Image Analysis System (Applied
Imaging, Santa Clara, CA) and karyotypes were arranged
according to Pearson et al. [43].
List of abbreviations
6TG: 6-thioguanine; 8AG: 8-azaguanine; ATM: Ataxia tel-
angiectasia mutated gene; B-gal: beta-galactosidase; FBS:
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fetal bovine serum; G418: Geneticin (neomycin analog);
HPRT: hypoxanthine guanine phosphoribosyl transferase
HTERT: human telomerase reverse transcriptase; IRES:
internal ribosomal entry site; LB: Luria broth; NEOr: neo-
mycin phosphotransferase resistance cassette; NHP: Non
human primates;PBS: phosphate buffered saline; PCR:
polymerase chain reaction; PGK: phosphoglycerate kinase
; PUROr: puromycin resistance cassette; TERT: telomerase
reverse transcriptase; UTR: untranslated region
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